Overview:
The Women's Cancers Program Area addresses research, clinical and educational activities for malignancies in women. The program fosters interactive and collaborative activities between and among members in order to develop multidisciplinary research in the areas of breast and women's reproductive cancers. It takes a comprehensive approach to clinical cancer research with a focus on translational research.
Goals:
Establish genetic-based risk assessment and counseling by understanding high-risk/genetic predisposition
Evaluate and implement prevention and screening strategies by understanding high-risk/genetic predisposition
Investigate the molecular/genetic and environmental conditions that give rise to cancers in women for possible early intervention by understanding early cellular transformation events
Develop targeted therapeutics for women’s cancers by understanding the mechanisms of solid tumor progression/angiogenesis/invasion
Identify targets and develop new, rational, highly effective and minimally toxic therapeutic approaches by understanding established tumors/motility/metastasis
Meetings and Events:
Multiple weekly clinical meetings within each of the clinics
Monthly Ovarian Cancer Research Group meetings
Monthly joint Cedars Sinai-UCLA gynecologic oncology journal club for fellows and residents
Bi-annual meeting of Women’s Cancers Program Area members, with oral and poster presentations and an invited visiting research expert
Leadership:
Dr. John Glaspy serves as director of the Women's Cancers Program Area and is the inaugural recipient of the Estelle, Abe and Marjorie Sanders Endowed Chair in Cancer Research at UCLA in recognition of his distinguished contributions in the area of cancer research and his eminence as a faculty member in the David Geffen School of Medicine. A professor of medicine, Glaspy earned a medical degree at UCLA concurrently with a master's degree in public health from the UCLA School of Public Health. He has gained a national reputation in clinical medicine as an acute diagnostician and outstanding clinician. His research includes understanding the role of gene therapy in cancer and developing new and more efficient molecularly targeted therapies for melanoma and breast cancer. Glaspy played a major role in developing a community-based oncology research network designed to bring UCLA expertise and clinical research programs to regional oncology offices in California and several surrounding states.
Associate Director Dr. Robin Farias-Eisner, a professor of obstetrics and gynecology, serves as Chief of Gynecologic Oncology at UCLA. His research interests include developing better treatments for cervical and uterine cancer and better detection and treatment for ovarian cancer. Farias-Eisner and his colleagues are working on developing a test for the early detection of ovarian cancer that could join the mammogram, colonoscopy, and pap smear in the screening arsenal and save thousands of lives now lost every year to the cancer known as the "silent killer." The simple blood test can detect ovarian cancer when there are no physical signs of disease - when ovaries appear normal and CA 125, a biomarker for ovarian cancer, is normal. In a small study, Farias-Eisner and his team were able to diagnose early stage ovarian cancer with 100 percent accuracy using a panel of four biomarkers that create a specific protein signature. The work currently is being confirmed in a larger study.
Tuesday
National Institute of Health Cancer Statistics
http://seer.cancer.gov Welcome to the Surveillance, Epidemiology and End Results (SEER) Program, a premier source for cancer statistics in the United States. We collect information on incidence, prevalence and survival from specific geographic areas representing 28 percent of the US population and compile reports on all of these plus cancer mortality for the entire country. Our site is intended for anyone interested in US cancer statistics or cancer surveillance methods.
Overview of the SEER ProgramThe Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (NCI) is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the US population. For more information on this, please view the SEER Research Data. SEER coverage includes 26 percent of African Americans, 41 percent of Hispanics, 43 percent of American Indians and Alaska Natives, 54 percent of Asians, and 71 percent of Hawaiian/Pacific Islanders. (Details are provided in the table: Number of Persons by Race and Hispanic Ethnicity for SEER Participants.)
The SEER Program registries routinely collect data on patient demographics, primary tumor site, tumor morphology and stage at diagnosis, first course of treatment, and follow-up for vital status. The SEER Program is the only comprehensive source of population-based information in the United States that includes stage of cancer at the time of diagnosis and patient survival data. The mortality data reported by SEER are provided by the National Center for Health Statistics. The population data used in calculating cancer rates is obtained periodically from the Census Bureau. Updated annually and provided as a public service in print and electronic formats, SEER data are used by thousands of researchers, clinicians, public health officials, legislators, policymakers, community groups, and the public.
NCI staff work with the North American Association of Central Cancer Registries (NAACCR) to guide all state registries to achieve data content and compatibility acceptable for pooling data and improving national estimates. The SEER team is developing computer applications to unify cancer registration systems and to analyze and disseminate population-based data. Use of surveillance data for research is being improved through Web-based access to the data and analytic tools, and linking with other national data sources. For example, a Web-based tool for public health officials and policy makers, State Cancer Profiles, provides a user-friendly interface for finding cancer statistics for specific states and counties. This Web site is a joint project between NCI and CDC and is part of the Cancer Control PLANET Web site which provides links to comprehensive cancer control resources for public health professionals. SEER staff also work with a number of collaborating organizations that are involved in cancer surveillance and related disciplines.
Read Goals of the SEER Program for more information about SEER's activites
Overview of the SEER ProgramThe Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (NCI) is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the US population. For more information on this, please view the SEER Research Data. SEER coverage includes 26 percent of African Americans, 41 percent of Hispanics, 43 percent of American Indians and Alaska Natives, 54 percent of Asians, and 71 percent of Hawaiian/Pacific Islanders. (Details are provided in the table: Number of Persons by Race and Hispanic Ethnicity for SEER Participants.)
The SEER Program registries routinely collect data on patient demographics, primary tumor site, tumor morphology and stage at diagnosis, first course of treatment, and follow-up for vital status. The SEER Program is the only comprehensive source of population-based information in the United States that includes stage of cancer at the time of diagnosis and patient survival data. The mortality data reported by SEER are provided by the National Center for Health Statistics. The population data used in calculating cancer rates is obtained periodically from the Census Bureau. Updated annually and provided as a public service in print and electronic formats, SEER data are used by thousands of researchers, clinicians, public health officials, legislators, policymakers, community groups, and the public.
NCI staff work with the North American Association of Central Cancer Registries (NAACCR) to guide all state registries to achieve data content and compatibility acceptable for pooling data and improving national estimates. The SEER team is developing computer applications to unify cancer registration systems and to analyze and disseminate population-based data. Use of surveillance data for research is being improved through Web-based access to the data and analytic tools, and linking with other national data sources. For example, a Web-based tool for public health officials and policy makers, State Cancer Profiles, provides a user-friendly interface for finding cancer statistics for specific states and counties. This Web site is a joint project between NCI and CDC and is part of the Cancer Control PLANET Web site which provides links to comprehensive cancer control resources for public health professionals. SEER staff also work with a number of collaborating organizations that are involved in cancer surveillance and related disciplines.
Read Goals of the SEER Program for more information about SEER's activites
Subscribe to:
Posts (Atom)